Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine in the Acute Management of Cardiogenic Shock (IVASHOCK)
NCT07714746Phase 3Recruiting
- Sponsor
- National Institute of Cardiovascular Diseases
- Start
- Apr 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
A Phase 3 trial of ivabradine in cardiogenic shock, sponsored by National Institute of Cardiovascular Diseases. Started Apr 2026; status: recruiting.
02
Drugs
ivabradine
03
Conditions
cardiogenic shock
Beyond the preview
Go deeper on NCT07714746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07714746.